Methods and compositions related to cooperative primers and reverse transcription
US-2024182992-A1 · Jun 6, 2024 · US
US9970067B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9970067-B2 |
| Application number | US-201514943894-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 17, 2015 |
| Priority date | Nov 21, 2014 |
| Publication date | May 15, 2018 |
| Grant date | May 15, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
This invention relates to primers and probes for detecting Ebola virus and one or more subtypes of Ebola virus as well as kits including the probes and primers and methods of using the probes and primers.
Opening claim text (preview).
What is claimed is: 1. A method of determining the presence of a viral hemorrhagic fever virus nucleic acid in a sample comprising: a) contacting the sample with at least one probe selected from a group consisting of SEQ ID:21, SEQ ID NO:22, SEQ ID NO: 23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO: 27, SEQ ID NO:28, SEQ ID NO:29, or SEQ ID:30 capable of hybridizing under stringent conditions to the viral hemorrhagic fever nucleic acid; and detecting hybridization between the viral hemorrhagic fever nucleic acid and the probe, wherein the detection of hybridization indicates the presence of the viral hemorrhagic fever virus nucleic acid in the sample; wherein the viral hemorrhagic fever virus nucleic acid is an Ebola virus nucleic acid; and wherein the Ebola virus nucleic acid is SEQ ID NO: 37. 2. The method of claim 1 , wherein the probe is labeled. 3. The method of claim 2 , wherein the probe is radiolabeled, or fluorescently labeled. 4. The method of claim 2 , wherein the probe is labeled with FAM and fluorescent quencher. 5. The method of claim 1 , further comprising amplifying the viral hemorrhagic fever nucleic acid by polymerase chain reaction (PCR), reverse transcriptase polymerase PCR (RT-PCR), or real time reverse transcriptase PCR (rt RT-PCR). 6. The method of claim 5 , wherein the amplifying employs primers that consist of the nucleotide sequences set forth as SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO: 13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO:20.
Specific hybridization probes · CPC title
from viruses · CPC title
for detection of mutation or polymorphism · CPC title
for diseases caused by alterations of genetic material · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.